Provided By GlobeNewswire
Last update: Mar 3, 2025
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025
Read more at globenewswire.comNASDAQ:APGE (6/12/2025, 2:11:02 PM)
43.37
+0.93 (+2.19%)
Find more stocks in the Stock Screener